Search results
Results from the WOW.Com Content Network
Primary fibrinogenolysis is a medical condition that appears with abnormal production of fibrinogen/fibrin degradation products (FDP), degradation of coagulation factors V, VIII, IX, XI and/or degradation of the fibrin present in any pre-existing localized thrombi and hemostatic clots.
Fibrinolysis is a process that prevents blood clots from growing and becoming problematic. [1] Primary fibrinolysis is a normal body process, while secondary fibrinolysis is the breakdown of clots due to a medicine, a medical disorder, or some other cause. [2] In fibrinolysis, a fibrin clot, the product of coagulation, is broken down. [3]
Primary fibrinogenolysis is the pathological lysis of fibrinogen characterized with a low fibrinogen, high fibrin degradation products, prolonged prothrombin time and activated partial thromboplastin time, a normal platelet count and absence of microcirculatory thrombosis.
Thrombolysis, also called fibrinolytic therapy, is the breakdown of blood clots formed in blood vessels, using medication.It is used in ST elevation myocardial infarction, stroke, and in cases of severe venous thromboembolism (massive pulmonary embolism or extensive deep vein thrombosis).
Coagulation activation markers are biomarkers of net activation of coagulation and fibrinolysis. [1] [2] Examples include prothrombin fragment 1+2 (F1+2), thrombin–antithrombin complex (TAT), fibrinopeptide A (FpA), fibrin monomers (FMs), plasmin-α 2-antiplasmin complex (PAP), activated protein C–protein C inhibitor (APC-PCI), and D-dimer (DD).
The euglobulin lysis time (ELT) is a test that measures overall fibrinolysis. The test is performed by mixing citrated platelet-poor plasma with acid in a glass test tube. This acidification causes the precipitation of certain clotting factors in a complex called the euglobulin fraction .
The fibrinolysis system is responsible for removing blood clots. Hyperfibrinolysis describes a situation with markedly enhanced fibrinolytic activity, resulting in increased, sometimes catastrophic bleeding. Hyperfibrinolysis can be caused by acquired or congenital reasons.
Fibrinogen disorders are a set of hereditary or acquired abnormalities in the quantity and/or quality of circulating fibrinogens.The disorders may lead to pathological bleeding and/or blood clotting or the deposition of fibrinogen in the liver, kidneys, or other organs and tissues.